Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 U.S.C. 355-1 Risk evaluation and mitigation strategies
21 U.S.C. 355-1 Risk evaluation and mitigation strategies, “Risk evaluation and mitigation strategies”, is a U.S. Code section of Part A—Drugs and Devices; in force.
https://ontology.bommaritollc.com/id/01a0f06c-ccd7-7652-842e-3b43e4a564b5
Elsewhere
Facts
| adms:identifier | |
| eli:cites | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 U.S.C. 355-1 |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Risk evaluation and mitigation strategiesen |
| schema:url | |
| skos:prefLabel | 21 U.S.C. 355-1 Risk evaluation and mitigation strategiesen |
Related
Amended by (7)eli:amends
- Pub. L. 112-144
- Pub. L. 113-5
- Pub. L. 114-255
- Pub. L. 115-271
- Pub. L. 115-52
- Pub. L. 116-94
- Pub. L. 117-328
Cited by (7)eli:cites
- 21 U.S.C. 333 Penalties
- 21 U.S.C. 352 Misbranded drugs and devices
- 21 U.S.C. 353b Outsourcing facilities
- 21 U.S.C. 353d Process to update labeling for certain generic drugs
- 21 U.S.C. 355 New drugs
- 21 U.S.C. 355-2 Actions for delays of generic drugs and biosimilar biological products
- 45 CFR 102.3 Penalty adjustment and table.